Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Major Database Launched to Aid Vaccine Development Worldwide

By LabMedica International staff writers
Posted on 28 May 2009
Key improvements in a major infectious disease database that will aid vaccine development worldwide were unveiled with the 2.0 launch of a vaccine database and analysis resource.

The U.S. More...
National Institutes of Health- (NIH; Bethesda, MD, USA) sponsored Immune Epitope Database and Analysis Resource (IEDB) 2.0 launch was announced by researchers from the La Jolla Institute for Allergy & Immunology (La Jolla, CA, USA), who designed, developed, and continue to host the database under a multimillion dollar NIH contract.

The IEDB is the world's largest collection of scientific data on how the immune system responds to infectious diseases, and it is freely available online to researchers worldwide. "With this new version, we have curated hundreds of thousands of experimental data points and created a simplified search process that will significantly assist researchers around the globe in their efforts to develop new and better vaccines,” said Alessandro Sette, Ph.D., the IEDB's lead scientist and director of the La Jolla Institute's Center for Infectious Disease.

While the 2.0 launch was not timed to coincide with the swine flu outbreak, it nonetheless points up the importance of such public health tools, reported Bjoern Peters, Ph.D., the database's coprincipal investigator for bioinformatics. "The IEDB provides data on more than 50,000 epitopes, which are the sites on a virus that the immune system targets for attack. This information is key for researchers in developing new treatments, vaccines, and diagnostics,” said Dr. Peters. "Researchers will undoubtedly tap into the database in working to combat swine flu as well as other emerging or reemerging infectious diseases such as tuberculosis, West Nile virus, and dengue fever.”

The IEDB was originally launched in 2006 in the midst of bioterrorism concerns and was financed via the federal biodefense research program. "The idea was to create a central, searchable information resource that would allow researchers worldwide to quickly share and analyze data in an unprecedented manner,” said Stephen Wilson, Ph.D., the IEDB's project director. "In doing so, it would accelerate the development of new and better vaccines. Researchers would not have to reinvent the wheel when conducting experiments. Instead, they could go to the IEDB and view and analyze all immune epitope data previously published, which related to their work.”

The La Jolla Institute received the contract for developing the database in 2004 under a competitive bid process via the National Institutes of Allergy & Infectious Diseases, part of the National Institutes of Health. Creating the database meant gathering information from thousands of separate research articles published over several decades. It also meant designing a first-ever format. "We were creating a repository and method of data sharing that had never existed before,” Dr. Wilson said. In its first iteration, released in 2006, Institute developers took a more bioinformatics approach, presenting the data in a heavily analytic format. With the 2.0 launch, the Institute now had the benefit of user feedback, according to Dr. Wilson, and could make the database easier to search, focusing more specifically on key terms and concepts used by biologists to mine data.

One vital element of this, according to Dr. Sette, was ensuring that the database used shared terms, labeling, and presentation formats common across various scientific databases now in use by researchers around the globe. "The modern researcher needs to be able to access all this information and to be able to jump from the genome database to the chemical structure database to the immune epitope database quickly with the assurance that the data are presented using similar formats for easy understandability,” he said.

To accomplish this goal, Dr. Peters noted that the Institute sought input from bioengineering computer experts and scientific leaders in the field. "This version taps into how the user really thinks and how they universally access data,” he said. "In addition, we've provided more computational tools that enable researchers to quickly analyze their data.”

Along with increased usability, the database's information resources have grown immensely over the last several years. "The 2.0 version catalogues over 95% of the published information currently available on the immune epitope response to infectious diseases, and is continuously updated,” Dr. Peters said.

Moreover, La Jolla Institute researchers are currently adding data on epitope responses to allergies and autoimmune diseases that will benefit researchers in those areas.

Related Links:

Epitope Database and Analysis Resource
National Institutes of Health
La Jolla Institute for Allergy & Immunology



Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Human Estradiol Assay
Human Estradiol CLIA Kit
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.